BRIEF published on 12/27/2024 at 07:35, 1 year 8 months ago Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial Gene Therapy Sensorion Hearing Loss SENS-501 Audiogene Trial
BRIEF published on 12/27/2024 at 07:35, 1 year 8 months ago Sensorion finalise le recrutement pour l'essai de phase 1/2 d'Audiogene Thérapie Génique Sensorion Perte Auditive SENS-501 Essai Audiogene
PRESS RELEASE published on 12/27/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases Sensorion completes enrollment of the first cohort in the Audiogene Phase 1/2 gene therapy clinical trial, targeting infants with hearing loss disorders Gene Therapy Clinical Trial Sensorion Hearing Loss Disorders Audiogene
BRIEF published on 12/18/2024 at 07:35, 1 year 8 months ago Sensorion présente des résultats préliminaires positifs pour le SENS-501 Essai Clinique Thérapie Génique Innovation Biotechnologique SENS-501 Surdité Congénitale
BRIEF published on 12/18/2024 at 07:35, 1 year 8 months ago Sensorion Reports Positive Preliminary Results for SENS-501 Gene Therapy Clinical Trial SENS-501 Congenital Deafness Biotechnological Innovation
PRESS RELEASE published on 12/18/2024 at 07:30, 1 year 8 months ago Informations privilégiées / Autres communiqués Sensorion présente des données positives de l'essai clinique de Phase 1/2 de thérapie génique pour la surdité chez les nourrissons. Nouvelles données encourageantes sur SENS-501. Séminaire en ligne prévu pour 2025 Sécurité Thérapie Génique Phase 1/2 Sensorion Surdité
PRESS RELEASE published on 12/18/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases Sensorion reports positive safety data and behavioral changes in toddlers from the Audiogene Phase 1/2 Gene Therapy Clinical Trial. Plans KOL event in 2025 for further discussion Gene Therapy Clinical Trial Sensorion Hearing Loss Audiogene
BRIEF published on 11/06/2024 at 07:35, 1 year 10 months ago Sensorion to Join Key Investor Conferences in November 2024 Biotechnology Investor Conferences Sensorion Hearing Loss Therapies Gene Therapy Development
BRIEF published on 11/06/2024 at 07:35, 1 year 10 months ago Sensorion participera aux principales conférences d'investisseurs en novembre 2024 Biotechnologie Conférences D'investisseurs Sensorion Thérapies Pour La Perte Auditive Développement De La Thérapie Génique
PRESS RELEASE published on 11/06/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases Sensorion to participate in upcoming investor conferences in November 2024, including Stifel Healthcare Conference and LifeSci Capital & Sofinnova Partners Summit Biotechnology Investor Conferences Clinical-stage Sensorion Hearing Loss Disorders
Published on 09/08/2026 at 01:45, 2 hours 16 minutes ago Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 2 days 23 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 4 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 5 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 5 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/07/2026 at 19:19, 8 hours 42 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 9 hours 1 minute ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 9 hours 19 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 10 hours 1 minute ago E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 10 hours 16 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 09/07/2026 at 19:00, 9 hours 1 minute ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 9 hours 1 minute ago Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 9 hours 56 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 9 hours 56 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026
